Washington, DC (January 7, 2016) The Pharmaceutical Research and Manufacturers of America (PhRMA) has appointed Amy Jackson as its new representative in Japan. As PhRMA’s Japan Representative, Ms. Jackson will coordinate the activities of PhRMA’s office in Tokyo and advocate for America’s research-based pharmaceutical companies on government, economic and health care policy matters in Japan.
“Amy is a great addition to the PhRMA team,” said PhRMA President and CEO Stephen J.Ubl. “PhRMA seeks to be a constructive stakeholder in Japan’s health care system, helping to foster policies that ensure Japanese patients have timely access to state of the art medicines, and contributing to the development of Japan’s life sciences sector. Amy’s extensive experience in Asian economic and public policy issues with both the U.S. government and in the private sector make her an ideal choice to help us achieve these aims.”
Jackson comes to PhRMA after serving more than six years as President of tha AMCHAM Korea. Previously Jackson was a Mansfield scholar and worked for a member of the Japanese Diet. Jackson also held numerous positions at USTR and NASA, including Director of Japanese Affairs.
Jackson will succeed Ira Wolf, who has served as PhRMA’s Japan Representative since 2006. “Ira has been a tireless advocate for PhRMA in Japan these past ten years,” Ubl said, “and I want to thank him for his important contributions to our industry’s efforts there.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.